An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Clinical Trial Grant
Awarded By
ORIC Pharmaceuticals, Inc.
Start Date
December 11, 2024
End Date
November 26, 2029
Awarded By
ORIC Pharmaceuticals, Inc.
Start Date
December 11, 2024
End Date
November 26, 2029